{"gene":"PRDM2","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1995,"finding":"PRDM2/RIZ is a 250-kDa nuclear protein that directly binds the retinoblastoma protein (Rb) via an Rb-binding motif; the interaction was identified by cDNA library screening for Rb-binding proteins.","method":"cDNA library screening, binding assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding demonstrated in initial cloning paper, later confirmed by multiple orthogonal studies including NMR/ITC (PMID:25640033)","pmids":["7538672"],"is_preprint":false},{"year":1997,"finding":"The RIZ gene produces two protein products via an internal promoter: RIZ1 (280 kDa, contains the PR domain) and RIZ2 (250 kDa, lacks the PR domain). Both are nuclear proteins as determined by immunofluorescence after transfection.","method":"Immunoprecipitation, immunoblot, RNase protection assay, immunofluorescence, transfection","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal biochemical methods in one study, replicated across many subsequent studies","pmids":["9006946"],"is_preprint":false},{"year":1997,"finding":"RIZ1 and RIZ2 bind GC-rich/Sp1-binding elements via the first three zinc finger motifs and repress transcription; a repressor domain was mapped to the central region of the protein. RIZ1 more potently represses SV40 promoter than RIZ2, indicating the PR domain modulates repressor function.","method":"Recombinant protein DNA-binding assay, GAL4 fusion transcription reporter assay, transfection","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro DNA-binding with recombinant protein, domain-mapping with functional reporters, single lab but multiple orthogonal methods","pmids":["9334209"],"is_preprint":false},{"year":1997,"finding":"The acidic region of RIZ (containing IRCDE/CR2-like motif) specifically interacts with the E1A-binding domain of Rb, can form a ternary complex with Rb and E2F1, but does not bind the Rb family members p107 or p130 in vitro.","method":"In vitro binding assay, peptide competition, ternary complex formation","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with defined recombinant proteins, single lab","pmids":["9223517"],"is_preprint":false},{"year":1998,"finding":"Forced RIZ1 expression in breast cancer cells causes G2/M cell cycle arrest and/or apoptosis; RIZ2 is normally expressed in all breast cancer cases whereas RIZ1 is specifically lost, indicating selective tumor suppressive activity of the RIZ1 isoform.","method":"Adenoviral forced expression, flow cytometry cell cycle analysis, cell viability assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function/gain-of-function with defined phenotypic readout, replicated in multiple cancer types","pmids":["9766644"],"is_preprint":false},{"year":1999,"finding":"RIZ/PRDM2 protein co-immunoprecipitates with estrogen receptor (ERα) in cell extracts from cultured cells and target tissues in a ligand-dependent manner; mapping identified shared interaction regions. Estradiol induces redistribution of RIZ protein within the nucleus and cytoplasm in vitro and in vivo in rat endometrium.","method":"Co-immunoprecipitation, interaction domain mapping, immunolocalization in cultured cells and rat tissue","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with domain mapping, confirmed in vivo in animal tissue, replicated in later studies","pmids":["10706618"],"is_preprint":false},{"year":1999,"finding":"RIZ protein binds to a TTGGC DNA motif identified by CAST selection and co-immunoprecipitates with estrogen receptor from MCF-7 cell extracts; RIZ confers estrogen inducibility to a promoter containing this motif in transfection experiments.","method":"CAST (cyclic amplification and selection of target), EMSA, Co-IP, transfection reporter assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (CAST, EMSA, Co-IP, reporter), single lab","pmids":["10544042"],"is_preprint":false},{"year":2001,"finding":"Targeted inactivation of the RIZ1 locus (leaving RIZ2 intact) in mice causes a high incidence of diffuse large B-cell lymphomas and broad spectrum of tumors; missense mutations in human tumors cluster in the MTase (PR) domain and abolish RIZ1's capacity to enhance estrogen receptor transactivation.","method":"Targeted mouse knockout, tumor analysis, human tumor mutation sequencing, transcription activation assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout with defined tumor phenotype, functional assay of cancer-associated mutations, replicated mechanistically in multiple studies","pmids":["11544182"],"is_preprint":false},{"year":2001,"finding":"RIZ1 expression is selectively induced during retinoic acid-, TPA-, or vitamin D3-driven myeloid differentiation of HL60 cells with redistribution within the nucleus; forced RIZ1 expression arrests HL60 growth and causes cell death.","method":"RT-PCR, RNase protection assay, immunocytochemistry, adenoviral forced expression, cell viability assay","journal":"Molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization plus functional gain-of-function, single lab, multiple methods","pmids":["11591891"],"is_preprint":false},{"year":2004,"finding":"The RIZ1 P704 deletion polymorphism shows impaired co-activation of ERα in a ligand- and dose-dependent manner compared to the P704+ allele, establishing this region as functionally important for RIZ1's role as an ERα co-activator.","method":"In vitro transcription co-activation assay (reporter gene), comparison of polymorphic variants","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — functional in vitro assay with defined variants, single lab","pmids":["15579774"],"is_preprint":false},{"year":2005,"finding":"The PR domain of RIZ1 is structurally homologous to SET domains with a pseudo-knot at the C-terminus and flexible segments at the carboxyl terminus involved in H3K9 methylation; cancer-associated missense mutations map to the PR domain and reduce methyltransferase activity.","method":"Deuterium exchange mass spectrometry, domain mapping, selective deletion mutagenesis, crystallization","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — structural characterization by DXMS with mutagenesis, single lab","pmids":["15964548"],"is_preprint":false},{"year":2006,"finding":"RIZ1 (PRDM2) associates with the promoter region of IGF-1 and increases histone H3 lysine 9 methylation at that promoter; forced RIZ1 expression in CML blast crisis cell lines decreases IGF-1 receptor activation and downstream ERK1/2 and AKT signaling.","method":"Chromatin immunoprecipitation (ChIP), cDNA microarray, forced expression, Western blotting for signaling components, IGF-1 blocking antibody","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating promoter binding and H3K9 methylation combined with functional pathway analysis, single lab, multiple orthogonal methods","pmids":["16953217"],"is_preprint":false},{"year":2007,"finding":"The solution NMR structure of the RIZ1 PR domain reveals a typical SET fold including a C-terminal pseudo-knot; the domain does not have detectable affinity for the methyl donor by-product S-adenosyl-L-homocysteine (SAH) but interacts with a synthetic peptide comprising residues 1–20 of histone H3.","method":"NMR structure determination, SAH binding assay, histone H3 peptide binding","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — solution NMR structure with functional binding characterization, single lab but rigorous structural study","pmids":["18082620"],"is_preprint":false},{"year":2008,"finding":"RIZ1 is required for the cancer-preventive benefit of a methyl-balanced diet in mice; methyl-balanced diet upregulates RIZ1 expression, and higher RIZ1 activity correlates with increased H3K9 methylation at RIZ1 target gene promoters as shown by ChIP.","method":"Mouse dietary experiment (RIZ1 knockout vs. wild type), microarray gene expression, ChIP, quantitative RT-PCR","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic epistasis with ChIP functional readout, single lab","pmids":["18852888"],"is_preprint":false},{"year":2010,"finding":"RIZ1 epigenetic silencing in hepatocellular carcinoma involves both DNA promoter methylation and H3K9 trimethylation; 5-Aza-dC promotes conversion of H3K9me3 to H3K9ac at the RIZ1 promoter preceding re-expression; HDAC1 (but not HDAC3) is downregulated by 5-Aza-dC/TSA treatment.","method":"Chromatin immunoprecipitation (ChIP), methylation-specific PCR, RT-PCR, immunohistochemistry, demethylating/HDAC inhibitor treatment","journal":"Journal of hepatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating histone modification dynamics at promoter, single lab, multiple orthogonal methods","pmids":["20675009"],"is_preprint":false},{"year":2010,"finding":"RIZ1 expression is induced by RANKL in macrophage-like cells and is required for osteoclast formation; RIZ1 siRNA knockdown reduces NFATc1 expression and impairs TRAP-positive multinucleated osteoclast formation.","method":"siRNA knockdown, RANKL stimulation assay, TRAP staining, Western blotting for NFATc1","journal":"Immunology letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA loss-of-function with defined molecular and cellular phenotype, single lab","pmids":["20417662"],"is_preprint":false},{"year":2010,"finding":"RIZ1 expression induced by TNF-α in monocytic leukemia cells is dependent on NF-κB and AKT signaling; RIZ1 in turn augments p53 expression, and RIZ1 silencing prevents p53 induction, resulting in enhanced proliferation.","method":"Pathway inhibition, siRNA knockdown, Western blotting, proliferation assay","journal":"Cancer investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA loss-of-function with defined signaling pathway readout, single lab","pmids":["20594067"],"is_preprint":false},{"year":2012,"finding":"An estrogen-responsive element (ERE) within the RIZ promoter 2 (driving RIZ2 expression) is regulated in a ligand-specific manner by ERα through both its AF1 and AF2 domains; association of topoisomerase IIβ with this promoter confirms transcriptional activation by estrogen, with cyclical H3K9 methylation patterns comparable to other estrogen-regulated promoters.","method":"Promoter reporter assay, ChIP for ERα and histone modifications, topoisomerase IIβ ChIP, transfection with ERα domain mutants","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple ChIP assays plus functional reporter with domain mutants, single lab","pmids":["21503890"],"is_preprint":false},{"year":2014,"finding":"PR-Set7/KMT5a directly and specifically binds the C-terminus of Riz1/PRDM2; the PR/SET domain of Riz1 preferentially monomethylates H3K9; the PR-Set7-binding domain of Riz1 is required for its nuclear localization and for maintenance of the H4K20me1-H3K9me1 trans-tail histone code. Cancer-associated frameshift mutations truncating Riz1 and preventing PR-Set7 binding abolish tumor suppression; both the methyltransferase domain and PR-Set7-binding domain are required for tumor suppressor function.","method":"Direct binding assay (Co-IP, pulldown), H3K9 methyltransferase in vitro assay, nuclear localization by imaging, tumor suppression assay (proliferation/apoptosis), histone modification analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro enzymatic assay, direct binding, localization linked to function, domain mutagenesis with phenotypic readout, single rigorous study","pmids":["24423864"],"is_preprint":false},{"year":2015,"finding":"PRDM2/RIZ is enriched in quiescent muscle stem cells and controls reversible quiescence in cultured myoblasts; PRDM2 associates with >4400 promoters in G0 myoblasts (55% marked with H3K9me2), and knockdown alters histone methylation at Myogenin and CyclinA2 (CCNA2) promoters. PRDM2 protein interacts with PRC2 component EZH2 and regulates EZH2's association with a G0-specific bivalent chromatin domain at the CCNA2 locus, acting upstream of the PRC2 complex.","method":"ChIP-seq, ChIP-qPCR, siRNA knockdown, Co-IP (PRDM2-EZH2 interaction), flow cytometry, live imaging","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-seq, reciprocal Co-IP, functional knockdown with defined chromatin and cellular phenotype, multiple orthogonal methods","pmids":["26040698"],"is_preprint":false},{"year":2015,"finding":"The structural basis for RIZ1-Rb interaction was established: the acidic region (AR) of RIZ1 is intrinsically disordered and binds the pocket domain of Rb with submicromolar affinity; binding is mediated primarily by the short IRCDE motif within AR, analogous to the LXCXE motif of viral oncoproteins.","method":"NMR spectroscopy, isothermal titration calorimetry (ITC), fluorescence anisotropy, recombinant proteins","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple biophysical methods with recombinant proteins characterizing affinity and binding interface, single rigorous study","pmids":["25640033"],"is_preprint":false},{"year":2016,"finding":"History of alcohol dependence persistently decreases Prdm2 expression in the rat dorsomedial prefrontal cortex, with decreased H3K9me1; viral-vector knockdown of Prdm2 in dmPFC phenocopies dependence-induced increases in alcohol self-administration and compulsive drinking. ChIP-seq shows genes involved in synaptic communication are regulated by H3K9me1 in dependent rats.","method":"Viral vector knockdown in vivo, ChIP-seq for H3K9me1, behavioral assays, qRT-PCR","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo viral-vector loss-of-function with defined behavioral and epigenomic phenotype, ChIP-seq, multiple methods","pmids":["27573876"],"is_preprint":false},{"year":2017,"finding":"Somatic PRDM2 c.4467delA frameshift mutation in colorectal cancer cells reduces global H3K9 dimethylation; correction to wild-type by genome editing restores H3K9me2, reduces migration, anchorage-independent growth and tumor growth in vivo; gene set enrichment analysis identifies regulation of EMT (with VIM as most regulated gene) as a central aspect of PRDM2 tumor suppressive action.","method":"CRISPR/genome editing (isogenic cell line correction), global histone methylation analysis, migration assay, anchorage-independent growth, xenograft tumor model, gene set enrichment analysis","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 / Strong — isogenic genome-edited cell system with multiple orthogonal functional readouts and in vivo validation, single rigorous study","pmids":["29228717"],"is_preprint":false},{"year":2017,"finding":"HBx (hepatitis B virus X protein) represses RIZ1 expression by upregulating DNMT1, which binds the RIZ1 promoter (shown by ChIP); this interaction is enhanced by HBx. Decreased miR-152 is involved in DNMT1 upregulation in HBx-transfected cells.","method":"ChIP, siRNA knockdown of DNMT1, HBx transfection, bisulfite sequencing, methylation-specific PCR","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating DNMT1 promoter binding plus siRNA rescue, single lab","pmids":["28339081"],"is_preprint":false},{"year":2018,"finding":"RIZ1 directly binds the Akt3 gene promoter and represses its transcription with concomitant increase in H3K9 methylation at the promoter; overexpression of RIZ1 reduces Akt3 protein and luciferase reporter activity from the Akt3 promoter.","method":"In vitro promoter binding with recombinant protein, ChIP, luciferase reporter assay, Western blotting","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo promoter binding with functional reporter and histone modification readout, single lab","pmids":["29367689"],"is_preprint":false},{"year":2008,"finding":"YY1 protein binds the RIZ1 promoter and positively regulates its transcription in osteosarcoma cells; YY1 presence reduces H3K9 dimethylation at the promoter as shown by ChIP. Silencing of YY1 decreases RIZ1 protein expression.","method":"ChIP, promoter reporter assay, YY1 siRNA knockdown, RT-PCR, Western blot","journal":"Oncology research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus promoter assay and siRNA loss-of-function, single lab","pmids":["18488713"],"is_preprint":false},{"year":2015,"finding":"PRDM2 overexpression upregulates dopamine receptor D2 (D2DR) expression and inhibits ERK1/2 phosphorylation in MMQ prolactinoma cells; PRDM2 shows a synergistic effect with bromocriptine in inhibiting prolactin secretion and cell viability.","method":"Overexpression in cell line, Western blot for ERK phosphorylation, RT-PCR for D2DR, cell viability assay","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single lab, gain-of-function with defined signaling readout, moderate experimental rigor","pmids":["25884948"],"is_preprint":false},{"year":2009,"finding":"RIZ1 protein is localized to the nucleus in normal prostate epithelial cells; in cancer cells with higher Gleason score, RIZ1 shifts from nuclear to cytoplasmic localization. RIZ1 co-immunoprecipitates with both ERα and ERβ in estrogen-treated prostate epithelial cells.","method":"Immunohistochemistry, subcellular fractionation/localization, Co-IP with ERα and ERβ, RT-PCR","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Co-IP combined with localization in primary cells and tissue, single lab","pmids":["19746436"],"is_preprint":false},{"year":2020,"finding":"PRDM2 negatively regulates c-Myc expression in somatotroph adenoma GH3 cells; overexpression of PRDM2 induces G2/M arrest, apoptosis, and inhibits invasion, and elevates CDKN1A and CDKN1B levels. Combined with c-Myc inhibitor, PRDM2 further suppresses proliferation, establishing a functional PRDM2–c-Myc axis.","method":"Overexpression in GH3 cells, flow cytometry, transwell invasion assay, RT-PCR, Western blot, c-Myc inhibitor co-treatment","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — gain-of-function with molecular pathway readout and pharmacological epistasis, single lab","pmids":["32044406"],"is_preprint":false},{"year":2017,"finding":"RIZ1 negatively regulates UbcH10 (UBE2C) expression in a c-Myc-dependent manner in meningioma cells: RIZ1 overexpression decreases c-Myc which in turn reduces UbcH10, a c-Myc target gene, providing a RIZ1→c-Myc→UbcH10 regulatory axis.","method":"Overexpression, siRNA knockdown, Western blot, RT-PCR, reporter assay","journal":"American journal of translational research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, indirect epistasis inferred from expression changes, limited mechanistic validation","pmids":["28560012"],"is_preprint":false},{"year":2015,"finding":"The isolated N-terminal PR domain of RIZ1 possesses intrinsic histone methyltransferase activity and tumor-suppressive (growth-inhibitory) activity in meningioma cells; microarray analysis of PR-domain-treated cells identifies c-Myc and TXNIP as putative H3K9 methylation downstream targets.","method":"Recombinant TAT-RIZ1-PR protein transduction, histone methyltransferase activity assay, microarray, xenograft tumor model","journal":"Biomaterials","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro enzymatic assay for methyltransferase activity of PR domain, in vivo tumor model, single lab","pmids":["25934289"],"is_preprint":false},{"year":2015,"finding":"RIZ1 knockdown in cholangiocarcinoma CCA cells (which show predominant nuclear localization of RIZ1) augments cell proliferation and migration, defining RIZ1 as a regulator of these processes in this cell type.","method":"siRNA knockdown, nuclear localization by microscopy, proliferation assay, migration assay","journal":"Asian Pacific journal of cancer prevention","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, siRNA with phenotypic readout but limited mechanistic detail","pmids":["23098508"],"is_preprint":false},{"year":2025,"finding":"PRDM2 phosphosites Ser643 and Ser421 are the predominant phosphorylation sites across large-scale phosphoproteomics datasets; ATR kinase is computationally predicted to phosphorylate these sites; co-regulated phosphosites are enriched in DNA damage response pathways. However, this is a computational/bioinformatic study and functional consequences of phosphorylation were not experimentally validated.","method":"Computational phosphoproteomics meta-analysis, expression co-regulation analysis, kinase prediction","journal":"3 Biotech","confidence":"Low","confidence_rationale":"Tier 4 / Weak — purely computational/bioinformatic; no direct experimental validation of phosphosite function","pmids":["42179918"],"is_preprint":false}],"current_model":"PRDM2/RIZ1 is a nuclear histone H3 lysine 9 mono/dimethyltransferase whose N-terminal PR/SET domain catalyzes H3K9 methylation, represses transcription at GC-rich promoters, interacts with the retinoblastoma protein (Rb) via an IRCDE/LXCXE-like motif, forms a ligand-dependent complex with estrogen receptor α (acting as an ERα co-activator), and is recruited to target gene promoters (including IGF-1, Akt3, CyclinA2) where it deposits repressive H3K9me1/2 marks; its tumor suppressive activity requires both the PR/SET methyltransferase domain and a C-terminal domain that binds PR-Set7/KMT5a (which is also required for nuclear localization and the H4K20me1-H3K9me1 trans-tail histone code), while the oncogenic RIZ2 isoform, produced from an internal promoter and lacking the PR domain, promotes proliferation and can antagonize RIZ1 function in a yin-yang fashion."},"narrative":{"mechanistic_narrative":"PRDM2 (RIZ) is a nuclear, sequence-specific zinc-finger protein that functions as a histone H3 lysine 9 methyltransferase and transcriptional repressor, and acts as a tumor suppressor whose loss promotes proliferation and malignant transformation [PMID:11544182, PMID:29228717]. The gene encodes two products through an internal promoter: RIZ1, which contains the catalytic N-terminal PR/SET domain, and RIZ2, which lacks it; RIZ1 is selectively lost in cancers while RIZ2 is retained, and the PR domain modulates repressor potency [PMID:9006946, PMID:9334209, PMID:9766644]. The PR domain adopts a SET-like fold and possesses intrinsic methyltransferase activity, preferentially depositing repressive H3K9me1/2 marks; cancer-associated missense mutations cluster in this domain and reduce catalytic activity [PMID:15964548, PMID:18082620, PMID:24423864, PMID:25934289]. RIZ1 binds GC-rich/Sp1 elements through its first three zinc fingers and is recruited to target promoters including IGF-1 and Akt3, where it increases H3K9 methylation and dampens downstream ERK and AKT signaling [PMID:9334209, PMID:16953217, PMID:29367689]. Full tumor suppressor function requires both the PR/SET methyltransferase domain and a C-terminal domain that directly binds PR-Set7/KMT5a, which is also necessary for nuclear localization and for maintaining the H4K20me1–H3K9me1 trans-tail histone code; truncating frameshift mutations that prevent this interaction abolish tumor suppression [PMID:24423864]. PRDM2 also engages the chromatin machinery more broadly, interacting with the PRC2 component EZH2 to control bivalent chromatin and reversible quiescence at cell-cycle gene loci such as CCNA2 [PMID:26040698]. Beyond chromatin, RIZ1 binds the retinoblastoma protein via an intrinsically disordered acidic region carrying an IRCDE/LXCXE-like motif and can form a ternary complex with Rb and E2F1 [PMID:7538672, PMID:9223517, PMID:25640033], and it forms a ligand-dependent complex with estrogen receptor α acting as a co-activator [PMID:10706618, PMID:11544182]. PRDM2 is itself epigenetically silenced in tumors through DNA promoter methylation and H3K9 trimethylation, and its in vivo loss drives lymphoma and a broad tumor spectrum [PMID:11544182, PMID:20675009, PMID:29228717]. Functionally, PRDM2 controls cellular quiescence, differentiation, and epithelial–mesenchymal transition, and in the nervous system H3K9me1-dependent PRDM2 activity in the prefrontal cortex regulates alcohol-dependence behaviors [PMID:26040698, PMID:27573876, PMID:29228717].","teleology":[{"year":1995,"claim":"Identifying PRDM2/RIZ as a direct Rb-binding nuclear protein placed it within the retinoblastoma tumor suppressor network and motivated study of its growth-control role.","evidence":"cDNA library screening for Rb-binding proteins and binding assays","pmids":["7538672"],"confidence":"Medium","gaps":["Functional consequence of the Rb interaction not established","Binding interface not yet mapped"]},{"year":1997,"claim":"Establishing that an internal promoter generates PR-domain-containing RIZ1 and PR-domain-lacking RIZ2 defined the yin-yang isoform structure central to PRDM2 biology.","evidence":"Immunoprecipitation, immunoblot, RNase protection, immunofluorescence after transfection","pmids":["9006946"],"confidence":"High","gaps":["Catalytic role of the PR domain not yet demonstrated","Functional divergence of isoforms not yet established"]},{"year":1997,"claim":"Mapping DNA-binding to the first three zinc fingers and a central repressor domain, with stronger repression by RIZ1, showed the protein is a sequence-specific transcriptional repressor whose PR domain modulates activity.","evidence":"Recombinant DNA-binding assays, GAL4 reporter domain mapping, transfection; plus in vitro Rb-pocket ternary complex with E2F1","pmids":["9334209","9223517"],"confidence":"High","gaps":["In vivo target genes not identified","Link between DNA binding and histone modification not yet made"]},{"year":1998,"claim":"Demonstrating that RIZ1 (but not RIZ2) induces G2/M arrest and apoptosis and is selectively lost in breast cancer established isoform-specific tumor suppression.","evidence":"Adenoviral forced expression, flow cytometry, viability assays in breast cancer cells","pmids":["9766644"],"confidence":"High","gaps":["Molecular basis of growth arrest not defined","Mechanism of selective RIZ1 loss not addressed"]},{"year":1999,"claim":"Showing a ligand-dependent RIZ–ERα complex and estrogen-responsive promoter targeting expanded PRDM2's role into nuclear hormone receptor signaling.","evidence":"Co-IP, domain mapping, CAST/EMSA, reporter assays in MCF-7 and rat endometrium","pmids":["10706618","10544042"],"confidence":"High","gaps":["Whether co-activation involves methyltransferase activity unresolved","Direct vs indirect ERα contact not fully defined"]},{"year":2001,"claim":"Knockout of the RIZ1 locus causing lymphoma and tumors, with PR-domain mutations clustering in human cancers, provided genetic proof of tumor suppression centered on the methyltransferase domain.","evidence":"Targeted mouse knockout, human tumor mutation sequencing, ERα transactivation assays; plus differentiation induction in HL60 cells","pmids":["11544182","11591891"],"confidence":"High","gaps":["Enzymatic activity of the PR domain not yet directly measured","Direct substrate of the PR domain not yet defined"]},{"year":2007,"claim":"Solving the PR-domain structure as a SET-like fold that binds the H3 N-terminal peptide established the molecular basis for PRDM2 acting as an H3K9 methyltransferase.","evidence":"Solution NMR structure, SAH and H3 peptide binding assays; earlier DXMS structural mapping","pmids":["18082620","15964548"],"confidence":"High","gaps":["Catalytic mechanism and methyl-donor handling unclear (no SAH affinity detected)","Specific H3K9 lysine targeting not confirmed structurally"]},{"year":2006,"claim":"ChIP demonstrating RIZ1 occupancy and H3K9 methylation at the IGF-1 promoter with reduced downstream ERK/AKT signaling connected chromatin repression to a defined oncogenic signaling output.","evidence":"ChIP, microarray, forced expression, signaling Western blots in CML blast crisis cells","pmids":["16953217"],"confidence":"High","gaps":["Genome-wide target spectrum not yet defined","Direct vs indirect signaling effects not separated"]},{"year":2014,"claim":"Identifying direct KMT5a/PR-Set7 binding to the RIZ1 C-terminus as required for nuclear localization, the H4K20me1–H3K9me1 trans-tail code, and tumor suppression unified catalysis, localization, and cancer-associated truncations into one mechanistic model.","evidence":"Co-IP/pulldown, in vitro H3K9 methyltransferase assay, imaging, domain mutagenesis with phenotypic readout","pmids":["24423864"],"confidence":"High","gaps":["Stoichiometry and structure of the RIZ1–PR-Set7 complex unknown","How the trans-tail code is read by downstream factors unresolved"]},{"year":2015,"claim":"Defining the disordered acidic region with an IRCDE motif as the submicromolar Rb-pocket binding element clarified the structural basis of the long-known RIZ1–Rb interaction.","evidence":"NMR, ITC, fluorescence anisotropy with recombinant proteins","pmids":["25640033"],"confidence":"High","gaps":["Cellular consequence of competing with E2F for Rb not established","Regulation of the interaction in vivo unknown"]},{"year":2015,"claim":"Showing PRDM2 enrichment in quiescent muscle stem cells, genome-wide promoter occupancy with H3K9me2, and interaction with EZH2 positioned PRDM2 as an upstream regulator of bivalent chromatin and reversible quiescence.","evidence":"ChIP-seq, ChIP-qPCR, siRNA, Co-IP, flow cytometry, live imaging; plus isolated PR-domain transduction with intrinsic HMT activity","pmids":["26040698","25934289"],"confidence":"High","gaps":["Mechanism of PRDM2-directed EZH2 recruitment not defined","Relationship between H3K9me2 and PRC2-deposited marks at shared loci unresolved"]},{"year":2016,"claim":"In vivo viral knockdown linking PRDM2/H3K9me1 loss in the prefrontal cortex to compulsive alcohol drinking extended PRDM2's epigenetic function to neurobehavioral regulation.","evidence":"Viral-vector knockdown, ChIP-seq for H3K9me1, behavioral assays in rats","pmids":["27573876"],"confidence":"High","gaps":["Specific synaptic target genes mediating behavior not pinpointed","Upstream signals lowering PRDM2 in dependence unclear"]},{"year":2017,"claim":"Isogenic correction of a somatic PRDM2 frameshift restoring global H3K9me2 and reversing EMT/tumor phenotypes provided causal evidence that catalytic loss drives malignancy through EMT regulation.","evidence":"CRISPR isogenic correction, global histone methylation analysis, migration/anchorage-independent growth, xenograft, GSEA in colorectal cancer; plus HBx/DNMT1-mediated promoter silencing","pmids":["29228717","28339081"],"confidence":"High","gaps":["Direct EMT target genes bound by PRDM2 not mapped","Whether VIM is a direct or indirect target unresolved"]},{"year":2024,"claim":"Accumulating gain/loss-of-function studies define recurrent PRDM2 regulatory axes (Akt3 repression, c-Myc/UBE2C and p53 modulation, D2DR upregulation) but their direct chromatin basis is incompletely resolved.","evidence":"Overexpression/knockdown with reporter, ChIP, and signaling readouts across prolactinoma, somatotroph, meningioma, and leukemia cells","pmids":["29367689","32044406","28560012","25884948","20594067","20417662"],"confidence":"Medium","gaps":["Direct vs indirect regulation of c-Myc/p53 not separated by chromatin occupancy","Several axes rest on single-lab overexpression studies"]},{"year":null,"claim":"How PRDM2 activity is post-translationally controlled and how its catalytic and scaffolding functions are integrated to direct target selectivity remain open.","evidence":"No experimentally validated regulatory mechanism in the timeline; phosphosite/ATR predictions are computational only","pmids":[],"confidence":"Low","gaps":["Phosphorylation sites Ser643/Ser421 and ATR regulation not experimentally validated","No structure of full-length PRDM2 or its multiprotein complexes","Rules governing genome-wide target promoter selection unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[10,18,22,30]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,7,9,24]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[2,6,24]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[12,18]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,18,27,31]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[11,19,22]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[11,18,19,22]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,24]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[4,19,28]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[7,22]}],"complexes":[],"partners":["RB1","ESR1","KMT5A","EZH2","ESR2","E2F1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13029","full_name":"PR domain zinc finger protein 2","aliases":["GATA-3-binding protein G3B","Lysine N-methyltransferase 8","MTB-ZF","MTE-binding protein","PR domain-containing protein 2","Retinoblastoma protein-interacting zinc finger protein","Zinc finger protein RIZ"],"length_aa":1718,"mass_kda":188.9,"function":"S-adenosyl-L-methionine-dependent histone methyltransferase that specifically methylates 'Lys-9' of histone H3. May function as a DNA-binding transcription factor. Binds to the macrophage-specific TPA-responsive element (MTE) of the HMOX1 (heme oxygenase 1) gene and may act as a transcriptional activator of this gene","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q13029/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRDM2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"HIST2H2BE","stoichiometry":0.2},{"gene":"HMGN5","stoichiometry":0.2},{"gene":"NUMA1","stoichiometry":0.2},{"gene":"SMARCA1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/PRDM2","total_profiled":1310},"omim":[{"mim_id":"618319","title":"PR DOMAIN-CONTAINING PROTEIN 10; PRDM10","url":"https://www.omim.org/entry/618319"},{"mim_id":"614161","title":"PR DOMAIN-CONTAINING PROTEIN 5; PRDM5","url":"https://www.omim.org/entry/614161"},{"mim_id":"605780","title":"PR DOMAIN-CONTAINING PROTEIN 4; PRDM4","url":"https://www.omim.org/entry/605780"},{"mim_id":"601196","title":"PR DOMAIN-CONTAINING PROTEIN 2; PRDM2","url":"https://www.omim.org/entry/601196"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Golgi apparatus","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PRDM2"},"hgnc":{"alias_symbol":["RIZ","RIZ1","RIZ2","KMT8","MTB-ZF","HUMHOXY1","KMT8A"],"prev_symbol":[]},"alphafold":{"accession":"Q13029","domains":[{"cath_id":"2.170.270.10","chopping":"10-169","consensus_level":"medium","plddt":83.908,"start":10,"end":169},{"cath_id":"3.30.160","chopping":"359-414","consensus_level":"medium","plddt":80.578,"start":359,"end":414},{"cath_id":"-","chopping":"1161-1231","consensus_level":"medium","plddt":74.8131,"start":1161,"end":1231}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13029","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13029-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13029-F1-predicted_aligned_error_v6.png","plddt_mean":46.78},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRDM2","jax_strain_url":"https://www.jax.org/strain/search?query=PRDM2"},"sequence":{"accession":"Q13029","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13029.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13029/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13029"}},"corpus_meta":[{"pmid":"11544182","id":"PMC_11544182","title":"Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily.","date":"2001","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/11544182","citation_count":165,"is_preprint":false},{"pmid":"7538672","id":"PMC_7538672","title":"The retinoblastoma protein binds to RIZ, a zinc-finger protein that shares an epitope with the adenovirus E1A protein.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7538672","citation_count":162,"is_preprint":false},{"pmid":"11719434","id":"PMC_11719434","title":"Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11719434","citation_count":150,"is_preprint":false},{"pmid":"10688904","id":"PMC_10688904","title":"Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10688904","citation_count":147,"is_preprint":false},{"pmid":"9766644","id":"PMC_9766644","title":"RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9766644","citation_count":131,"is_preprint":false},{"pmid":"9006946","id":"PMC_9006946","title":"The retinoblastoma interacting zinc finger gene RIZ produces a PR domain-lacking product through an internal promoter.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9006946","citation_count":90,"is_preprint":false},{"pmid":"10508492","id":"PMC_10508492","title":"Decreased RIZ1 expression but not RIZ2 in hepatoma and suppression of hepatoma tumorigenicity by RIZ1.","date":"1999","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10508492","citation_count":88,"is_preprint":false},{"pmid":"10987271","id":"PMC_10987271","title":"Frequent frameshift mutations of RIZ in sporadic gastrointestinal and endometrial carcinomas with microsatellite instability.","date":"2000","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/10987271","citation_count":79,"is_preprint":false},{"pmid":"10862032","id":"PMC_10862032","title":"Mapping of a minimal deleted region in human hepatocellular carcinoma to 1p36.13-p36.23 and mutational analysis of the RIZ (PRDM2) gene localized to the region.","date":"2000","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10862032","citation_count":62,"is_preprint":false},{"pmid":"11280725","id":"PMC_11280725","title":"Adenovirus expressing RIZ1 in tumor suppressor gene therapy of microsatellite-unstable colorectal cancers.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11280725","citation_count":56,"is_preprint":false},{"pmid":"20675009","id":"PMC_20675009","title":"Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications.","date":"2010","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/20675009","citation_count":55,"is_preprint":false},{"pmid":"15069684","id":"PMC_15069684","title":"Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma.","date":"2004","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/15069684","citation_count":53,"is_preprint":false},{"pmid":"14534544","id":"PMC_14534544","title":"Biallelic inactivation of the RIZ1 gene in human gastric cancer.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14534544","citation_count":48,"is_preprint":false},{"pmid":"16953217","id":"PMC_16953217","title":"RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16953217","citation_count":48,"is_preprint":false},{"pmid":"11135439","id":"PMC_11135439","title":"RIZ, the retinoblastoma protein interacting zinc finger gene, is mutated in genetically unstable cancers of the pancreas, stomach, and colorectum.","date":"2001","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11135439","citation_count":47,"is_preprint":false},{"pmid":"10706618","id":"PMC_10706618","title":"The retinoblastoma-interacting zinc-finger protein RIZ is a downstream effector of estrogen action.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10706618","citation_count":46,"is_preprint":false},{"pmid":"15964548","id":"PMC_15964548","title":"Characterization of the PR domain of RIZ1 histone methyltransferase.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15964548","citation_count":45,"is_preprint":false},{"pmid":"26040698","id":"PMC_26040698","title":"A fine balance: epigenetic control of cellular quiescence by the tumor suppressor PRDM2/RIZ at a bivalent domain in the cyclin a gene.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26040698","citation_count":43,"is_preprint":false},{"pmid":"27573876","id":"PMC_27573876","title":"Dependence-induced increase of alcohol self-administration and compulsive drinking mediated by the histone methyltransferase PRDM2.","date":"2016","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/27573876","citation_count":43,"is_preprint":false},{"pmid":"8661032","id":"PMC_8661032","title":"Physical mapping of the retinoblastoma interacting zinc finger gene RIZ to D1S228 on chromosome 1p36.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8661032","citation_count":43,"is_preprint":false},{"pmid":"9334209","id":"PMC_9334209","title":"Transcriptional repression mediated by the PR domain zinc finger gene RIZ.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9334209","citation_count":42,"is_preprint":false},{"pmid":"12472571","id":"PMC_12472571","title":"Altered expression of retinoblastoma protein-interacting zinc finger gene, RIZ, in human leukaemia.","date":"2002","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/12472571","citation_count":41,"is_preprint":false},{"pmid":"17103461","id":"PMC_17103461","title":"RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma.","date":"2006","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17103461","citation_count":41,"is_preprint":false},{"pmid":"10369808","id":"PMC_10369808","title":"The retinoblastoma protein-interacting zinc finger gene RIZ in 1p36-linked cancers.","date":"1999","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/10369808","citation_count":37,"is_preprint":false},{"pmid":"14668725","id":"PMC_14668725","title":"Intragenic allelic loss and promoter hypermethylation of the RIZ1 tumor suppressor gene in parathyroid tumors and pheochromocytomas.","date":"2003","source":"Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/14668725","citation_count":37,"is_preprint":false},{"pmid":"12631603","id":"PMC_12631603","title":"Detection of hypermethylated RIZ1 gene in primary tumor, mouth, and throat rinsing fluid, nasopharyngeal swab, and peripheral blood of nasopharyngeal carcinoma patient.","date":"2003","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/12631603","citation_count":35,"is_preprint":false},{"pmid":"11259086","id":"PMC_11259086","title":"Preferential loss of a polymorphic RIZ allele in human hepatocellular carcinoma.","date":"2001","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11259086","citation_count":32,"is_preprint":false},{"pmid":"24966940","id":"PMC_24966940","title":"Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells.","date":"2014","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24966940","citation_count":31,"is_preprint":false},{"pmid":"22614009","id":"PMC_22614009","title":"Retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1) dysregulation in human malignant meningiomas.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22614009","citation_count":31,"is_preprint":false},{"pmid":"12082534","id":"PMC_12082534","title":"Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12082534","citation_count":31,"is_preprint":false},{"pmid":"25884948","id":"PMC_25884948","title":"Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25884948","citation_count":30,"is_preprint":false},{"pmid":"26690953","id":"PMC_26690953","title":"RIZ1: a potential tumor suppressor in glioma.","date":"2015","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26690953","citation_count":28,"is_preprint":false},{"pmid":"28339081","id":"PMC_28339081","title":"HBx represses RIZ1 expression by DNA methyltransferase 1 involvement in decreased miR-152 in hepatocellular carcinoma.","date":"2017","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/28339081","citation_count":28,"is_preprint":false},{"pmid":"14760116","id":"PMC_14760116","title":"Clinicopathological significance of microsatellite instability and mutated RIZ in colorectal cancer.","date":"2004","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/14760116","citation_count":27,"is_preprint":false},{"pmid":"24423864","id":"PMC_24423864","title":"The PR-Set7 binding domain of Riz1 is required for the H4K20me1-H3K9me1 trans-tail 'histone code' and Riz1 tumor suppressor function.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/24423864","citation_count":26,"is_preprint":false},{"pmid":"10544042","id":"PMC_10544042","title":"Identification of a DNA binding protein cooperating with estrogen receptor as RIZ (retinoblastoma interacting zinc finger protein).","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10544042","citation_count":26,"is_preprint":false},{"pmid":"17052263","id":"PMC_17052263","title":"DNA methylation of the RIZ1 gene is associated with nuclear accumulation of p53 in prostate cancer.","date":"2007","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/17052263","citation_count":25,"is_preprint":false},{"pmid":"27983647","id":"PMC_27983647","title":"Critical Function of PRDM2 in the Neoplastic Growth of Testicular Germ Cell Tumors.","date":"2016","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/27983647","citation_count":24,"is_preprint":false},{"pmid":"24993551","id":"PMC_24993551","title":"Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24993551","citation_count":24,"is_preprint":false},{"pmid":"29883756","id":"PMC_29883756","title":"Human PRDM2: Structure, function and pathophysiology.","date":"2018","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/29883756","citation_count":23,"is_preprint":false},{"pmid":"18712668","id":"PMC_18712668","title":"Hyper-methylation of RIZ1 tumor suppressor gene is involved in the early tumorigenesis of hepatocellular carcinoma.","date":"2008","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/18712668","citation_count":23,"is_preprint":false},{"pmid":"21503890","id":"PMC_21503890","title":"Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21503890","citation_count":21,"is_preprint":false},{"pmid":"15809732","id":"PMC_15809732","title":"Deletions and altered expression of the RIZ1 tumour suppressor gene in 1p36 in pheochromocytomas and abdominal paragangliomas.","date":"2005","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15809732","citation_count":21,"is_preprint":false},{"pmid":"18852888","id":"PMC_18852888","title":"Requirement of RIZ1 for cancer prevention by methyl-balanced diet.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18852888","citation_count":20,"is_preprint":false},{"pmid":"28718376","id":"PMC_28718376","title":"RIZ1 and histone methylation status in pituitary adenomas.","date":"2017","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28718376","citation_count":19,"is_preprint":false},{"pmid":"19602237","id":"PMC_19602237","title":"RIZ1 is potential CML tumor suppressor that is down-regulated during disease progression.","date":"2009","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19602237","citation_count":18,"is_preprint":false},{"pmid":"19746436","id":"PMC_19746436","title":"Expression of RIZ1 protein (Retinoblastoma-interacting zinc-finger protein 1) in prostate cancer epithelial cells changes with cancer grade progression and is modulated in vitro by DHT and E2.","date":"2009","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19746436","citation_count":18,"is_preprint":false},{"pmid":"26622888","id":"PMC_26622888","title":"Detecting abnormal methylation of tumor suppressor genes GSTP1, P16, RIZ1, and RASSF1A in hepatocellular carcinoma and its clinical significance.","date":"2015","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26622888","citation_count":18,"is_preprint":false},{"pmid":"11748455","id":"PMC_11748455","title":"The tumor suppressor gene RIZ in cancer gene therapy (review).","date":"2002","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/11748455","citation_count":17,"is_preprint":false},{"pmid":"22363126","id":"PMC_22363126","title":"Study on RIZ1 gene promoter methylation status in human esophageal squamous cell carcinoma.","date":"2012","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/22363126","citation_count":16,"is_preprint":false},{"pmid":"29228717","id":"PMC_29228717","title":"Somatic PRDM2 c.4467delA mutations in colorectal cancers control histone methylation and tumor growth.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29228717","citation_count":16,"is_preprint":false},{"pmid":"25934289","id":"PMC_25934289","title":"The transducible TAT-RIZ1-PR protein exerts histone methyltransferase activity and tumor-suppressive functions in human malignant meningiomas.","date":"2015","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/25934289","citation_count":15,"is_preprint":false},{"pmid":"20523343","id":"PMC_20523343","title":"Effects of triptolide on RIZ1 expression, proliferation, and apoptosis in multiple myeloma U266 cells.","date":"2010","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/20523343","citation_count":14,"is_preprint":false},{"pmid":"20594067","id":"PMC_20594067","title":"Retinoblastoma protein-interacting zinc finger 1 (RIZ1) regulates the proliferation of monocytic leukemia cells via activation of p53.","date":"2010","source":"Cancer investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20594067","citation_count":14,"is_preprint":false},{"pmid":"15579774","id":"PMC_15579774","title":"A deletion polymorphism in the RIZ gene, a female sex steroid hormone receptor coactivator, exhibits decreased response to estrogen in vitro and associates with low bone mineral density in young Swedish women.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15579774","citation_count":14,"is_preprint":false},{"pmid":"15488642","id":"PMC_15488642","title":"The Zn-finger domain of RIZ protein promotes MCF-7 cell proliferation.","date":"2004","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/15488642","citation_count":13,"is_preprint":false},{"pmid":"21369371","id":"PMC_21369371","title":"Anticancer activity of the PR domain of tumor suppressor RIZ1.","date":"2011","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21369371","citation_count":13,"is_preprint":false},{"pmid":"17693662","id":"PMC_17693662","title":"Genetic polymorphisms in the Rb-binding zinc finger gene RIZ and the risk of lung cancer.","date":"2007","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17693662","citation_count":13,"is_preprint":false},{"pmid":"11591891","id":"PMC_11591891","title":"Differentiation of myeloid cell lines correlates with a selective expression of RIZ protein.","date":"2001","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/11591891","citation_count":12,"is_preprint":false},{"pmid":"26709097","id":"PMC_26709097","title":"Tumor suppressor RIZ1 in obesity and the PI3K/AKT/mTOR pathway.","date":"2015","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26709097","citation_count":12,"is_preprint":false},{"pmid":"33585202","id":"PMC_33585202","title":"Searching for a Putative Mechanism of RIZ2 Tumor-Promoting Function in Cancer Models.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33585202","citation_count":12,"is_preprint":false},{"pmid":"20828818","id":"PMC_20828818","title":"Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia.","date":"2010","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/20828818","citation_count":12,"is_preprint":false},{"pmid":"20878080","id":"PMC_20878080","title":"Suppression of RIZ in biologically unfavourable neuroblastomas.","date":"2010","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20878080","citation_count":12,"is_preprint":false},{"pmid":"18037365","id":"PMC_18037365","title":"The RIZ Pro704 insertion-deletion polymorphism, bone mineral density and fracture risk: the Rotterdam study.","date":"2007","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/18037365","citation_count":12,"is_preprint":false},{"pmid":"18082620","id":"PMC_18082620","title":"Structural studies of the SET domain from RIZ1 tumor suppressor.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18082620","citation_count":12,"is_preprint":false},{"pmid":"18488713","id":"PMC_18488713","title":"Silencing of YY1 downregulates RIZ1 promoter in human osteosarcoma.","date":"2008","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/18488713","citation_count":11,"is_preprint":false},{"pmid":"9223517","id":"PMC_9223517","title":"In vitro analysis of the E1A-homologous sequences of RIZ.","date":"1997","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/9223517","citation_count":11,"is_preprint":false},{"pmid":"15309726","id":"PMC_15309726","title":"Detection of frameshift mutations of RIZ in gastric cancers with microsatellite instability.","date":"2004","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15309726","citation_count":11,"is_preprint":false},{"pmid":"15711769","id":"PMC_15711769","title":"Mutational study of the 1p located genes p18ink4c, Patched-2, RIZ1 and KIF1B in oligodendrogliomas.","date":"2005","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/15711769","citation_count":11,"is_preprint":false},{"pmid":"20417662","id":"PMC_20417662","title":"Retinoblastoma protein-interacting zinc finger 1 (RIZ1) participates in RANKL-induced osteoclast formation via regulation of NFATc1 expression.","date":"2010","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/20417662","citation_count":11,"is_preprint":false},{"pmid":"29575614","id":"PMC_29575614","title":"Combination of RIZ1 Overexpression and Radiotherapy Contributes to Apoptosis and DNA Damage of HeLa and SiHa Cervical Cancer Cells.","date":"2018","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/29575614","citation_count":10,"is_preprint":false},{"pmid":"20159667","id":"PMC_20159667","title":"DNA methylation of the RIZ1 tumor suppressor gene plays an important role in the tumorigenesis of cervical cancer.","date":"2010","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/20159667","citation_count":10,"is_preprint":false},{"pmid":"32044406","id":"PMC_32044406","title":"The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32044406","citation_count":10,"is_preprint":false},{"pmid":"17922684","id":"PMC_17922684","title":"Decreased expression of RIZ1 and its clinicopathological significance in epithelial ovarian carcinoma: correlation with epigenetic inactivation by aberrant DNA methylation.","date":"2007","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/17922684","citation_count":10,"is_preprint":false},{"pmid":"36964555","id":"PMC_36964555","title":"Exploring the putative role of PRDM1 and PRDM2 transcripts as mediators of T lymphocyte activation.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36964555","citation_count":9,"is_preprint":false},{"pmid":"29367689","id":"PMC_29367689","title":"Repression of Akt3 gene transcription by the tumor suppressor RIZ1.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29367689","citation_count":9,"is_preprint":false},{"pmid":"37853459","id":"PMC_37853459","title":"RIZ2 at the crossroad of the EGF/EGFR signaling in colorectal cancer.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37853459","citation_count":9,"is_preprint":false},{"pmid":"28528974","id":"PMC_28528974","title":"RIZ1 is regulated by estrogen and suppresses tumor progression in endometrial cancer.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28528974","citation_count":9,"is_preprint":false},{"pmid":"28560012","id":"PMC_28560012","title":"RIZ1 negatively regulates ubiquitin-conjugating enzyme E2C/UbcH10 via targeting c-Myc in meningioma.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/28560012","citation_count":9,"is_preprint":false},{"pmid":"32964965","id":"PMC_32964965","title":"Inactivation of lncRNA HOTAIRM1 caused by histone methyltransferase RIZ1 accelerated the proliferation and invasion of liver cancer.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32964965","citation_count":9,"is_preprint":false},{"pmid":"12002276","id":"PMC_12002276","title":"Nucleotide alteration of retinoblastoma protein-interacting zinc finger gene, RIZ, in human leukemia.","date":"2002","source":"The Tohoku journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12002276","citation_count":8,"is_preprint":false},{"pmid":"22300346","id":"PMC_22300346","title":"Aberrant methylation and decreased expression of the RIZ1 gene are frequent in adult acute lymphoblastic leukemia of T-cell phenotype.","date":"2012","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/22300346","citation_count":8,"is_preprint":false},{"pmid":"27713401","id":"PMC_27713401","title":"Synergism between RIZ1 gene therapy and paclitaxel in SiHa cervical cancer cells.","date":"2016","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27713401","citation_count":7,"is_preprint":false},{"pmid":"25987089","id":"PMC_25987089","title":"Aberrant Methylation of the 1p36 Tumor Suppressor Gene RIZ1 in Renal Cell Carcinoma.","date":"2015","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/25987089","citation_count":6,"is_preprint":false},{"pmid":"19325838","id":"PMC_19325838","title":"Cloning, expression, purification and crystallization of the PR domain of human retinoblastoma protein-binding zinc finger protein 1 (RIZ1).","date":"2008","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19325838","citation_count":6,"is_preprint":false},{"pmid":"22993552","id":"PMC_22993552","title":"Genetic and epigenetic alterations of RIZ1 and the correlation to clinicopathological parameters in liver fluke-related cholangiocarcinoma.","date":"2010","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22993552","citation_count":6,"is_preprint":false},{"pmid":"25640033","id":"PMC_25640033","title":"Structural and functional characterization of the acidic region from the RIZ tumor suppressor.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25640033","citation_count":5,"is_preprint":false},{"pmid":"23098508","id":"PMC_23098508","title":"Contribution of RIZ1 to regulation of proliferation and migration of a liver fluke-related cholangiocarcinoma cell.","date":"2012","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/23098508","citation_count":4,"is_preprint":false},{"pmid":"26697392","id":"PMC_26697392","title":"Identification of PRDM2 regulated genes in quiescent C2C12 myoblasts.","date":"2015","source":"Genomics data","url":"https://pubmed.ncbi.nlm.nih.gov/26697392","citation_count":4,"is_preprint":false},{"pmid":"38380944","id":"PMC_38380944","title":"Aberrant PRDM2 methylation as an early event in serrated lesions destined to evolve into microsatellite-instable colorectal cancers.","date":"2024","source":"The journal of pathology. Clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/38380944","citation_count":4,"is_preprint":false},{"pmid":"33639051","id":"PMC_33639051","title":"Effects of miR-362 in Regulating the Proliferation, Invasion and Apoptosis of Gastric Cancer by Inhibiting the Expression of Tumor-Promoting Factor PRDM2.","date":"2021","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/33639051","citation_count":3,"is_preprint":false},{"pmid":"27757741","id":"PMC_27757741","title":"Methylation Status of the RIZ1 Gene Promoter in Human Glioma Tissues and Cell Lines.","date":"2016","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27757741","citation_count":3,"is_preprint":false},{"pmid":"32391195","id":"PMC_32391195","title":"The predictive value of PRDM2 in solid tumor: a systematic review and meta-analysis.","date":"2020","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/32391195","citation_count":3,"is_preprint":false},{"pmid":"27830966","id":"PMC_27830966","title":"A deletion polymorphism in the RIZ gene is associated with increased progression of imatinib treated chronic myeloid leukemia patients.","date":"2016","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/27830966","citation_count":3,"is_preprint":false},{"pmid":"35908955","id":"PMC_35908955","title":"Therapeutic siRNA targeting the cancer cell stemness regulator PRDI-BF1 and RIZ domain zinc finger protein 14.","date":"2022","source":"Proceedings of the Japan Academy. Series B, Physical and biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35908955","citation_count":3,"is_preprint":false},{"pmid":"41273931","id":"PMC_41273931","title":"siRNA-based therapeutic candidate targeting PRDM2 for inhibition of lung cancer progression.","date":"2025","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/41273931","citation_count":2,"is_preprint":false},{"pmid":"37626944","id":"PMC_37626944","title":"Identification and Expressional Analysis of Putative PRDI-BF1 and RIZ Homology Domain-Containing Transcription Factors in Mulinia lateralis.","date":"2023","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/37626944","citation_count":1,"is_preprint":false},{"pmid":"41151301","id":"PMC_41151301","title":"Inhibition of AKT or mTOR molecules mitigates obesity-associated metabolic disorders in Riz1-/- mice with obesity.","date":"2025","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/41151301","citation_count":1,"is_preprint":false},{"pmid":"40867614","id":"PMC_40867614","title":"PRDM2-The Key Research Targets for the Development of Diseases in Various Systems.","date":"2025","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/40867614","citation_count":0,"is_preprint":false},{"pmid":"42179918","id":"PMC_42179918","title":"PRDM2 and DNA damage response: phosphoregulatory signaling insights.","date":"2026","source":"3 Biotech","url":"https://pubmed.ncbi.nlm.nih.gov/42179918","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50772,"output_tokens":7589,"usd":0.133076,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16942,"output_tokens":4916,"usd":0.103805,"stage2_stop_reason":"end_turn"},"total_usd":0.236881,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"PRDM2/RIZ is a 250-kDa nuclear protein that directly binds the retinoblastoma protein (Rb) via an Rb-binding motif; the interaction was identified by cDNA library screening for Rb-binding proteins.\",\n      \"method\": \"cDNA library screening, binding assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding demonstrated in initial cloning paper, later confirmed by multiple orthogonal studies including NMR/ITC (PMID:25640033)\",\n      \"pmids\": [\"7538672\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The RIZ gene produces two protein products via an internal promoter: RIZ1 (280 kDa, contains the PR domain) and RIZ2 (250 kDa, lacks the PR domain). Both are nuclear proteins as determined by immunofluorescence after transfection.\",\n      \"method\": \"Immunoprecipitation, immunoblot, RNase protection assay, immunofluorescence, transfection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal biochemical methods in one study, replicated across many subsequent studies\",\n      \"pmids\": [\"9006946\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"RIZ1 and RIZ2 bind GC-rich/Sp1-binding elements via the first three zinc finger motifs and repress transcription; a repressor domain was mapped to the central region of the protein. RIZ1 more potently represses SV40 promoter than RIZ2, indicating the PR domain modulates repressor function.\",\n      \"method\": \"Recombinant protein DNA-binding assay, GAL4 fusion transcription reporter assay, transfection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro DNA-binding with recombinant protein, domain-mapping with functional reporters, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"9334209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The acidic region of RIZ (containing IRCDE/CR2-like motif) specifically interacts with the E1A-binding domain of Rb, can form a ternary complex with Rb and E2F1, but does not bind the Rb family members p107 or p130 in vitro.\",\n      \"method\": \"In vitro binding assay, peptide competition, ternary complex formation\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with defined recombinant proteins, single lab\",\n      \"pmids\": [\"9223517\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Forced RIZ1 expression in breast cancer cells causes G2/M cell cycle arrest and/or apoptosis; RIZ2 is normally expressed in all breast cancer cases whereas RIZ1 is specifically lost, indicating selective tumor suppressive activity of the RIZ1 isoform.\",\n      \"method\": \"Adenoviral forced expression, flow cytometry cell cycle analysis, cell viability assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function/gain-of-function with defined phenotypic readout, replicated in multiple cancer types\",\n      \"pmids\": [\"9766644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RIZ/PRDM2 protein co-immunoprecipitates with estrogen receptor (ERα) in cell extracts from cultured cells and target tissues in a ligand-dependent manner; mapping identified shared interaction regions. Estradiol induces redistribution of RIZ protein within the nucleus and cytoplasm in vitro and in vivo in rat endometrium.\",\n      \"method\": \"Co-immunoprecipitation, interaction domain mapping, immunolocalization in cultured cells and rat tissue\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with domain mapping, confirmed in vivo in animal tissue, replicated in later studies\",\n      \"pmids\": [\"10706618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"RIZ protein binds to a TTGGC DNA motif identified by CAST selection and co-immunoprecipitates with estrogen receptor from MCF-7 cell extracts; RIZ confers estrogen inducibility to a promoter containing this motif in transfection experiments.\",\n      \"method\": \"CAST (cyclic amplification and selection of target), EMSA, Co-IP, transfection reporter assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (CAST, EMSA, Co-IP, reporter), single lab\",\n      \"pmids\": [\"10544042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Targeted inactivation of the RIZ1 locus (leaving RIZ2 intact) in mice causes a high incidence of diffuse large B-cell lymphomas and broad spectrum of tumors; missense mutations in human tumors cluster in the MTase (PR) domain and abolish RIZ1's capacity to enhance estrogen receptor transactivation.\",\n      \"method\": \"Targeted mouse knockout, tumor analysis, human tumor mutation sequencing, transcription activation assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout with defined tumor phenotype, functional assay of cancer-associated mutations, replicated mechanistically in multiple studies\",\n      \"pmids\": [\"11544182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RIZ1 expression is selectively induced during retinoic acid-, TPA-, or vitamin D3-driven myeloid differentiation of HL60 cells with redistribution within the nucleus; forced RIZ1 expression arrests HL60 growth and causes cell death.\",\n      \"method\": \"RT-PCR, RNase protection assay, immunocytochemistry, adenoviral forced expression, cell viability assay\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization plus functional gain-of-function, single lab, multiple methods\",\n      \"pmids\": [\"11591891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"The RIZ1 P704 deletion polymorphism shows impaired co-activation of ERα in a ligand- and dose-dependent manner compared to the P704+ allele, establishing this region as functionally important for RIZ1's role as an ERα co-activator.\",\n      \"method\": \"In vitro transcription co-activation assay (reporter gene), comparison of polymorphic variants\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — functional in vitro assay with defined variants, single lab\",\n      \"pmids\": [\"15579774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The PR domain of RIZ1 is structurally homologous to SET domains with a pseudo-knot at the C-terminus and flexible segments at the carboxyl terminus involved in H3K9 methylation; cancer-associated missense mutations map to the PR domain and reduce methyltransferase activity.\",\n      \"method\": \"Deuterium exchange mass spectrometry, domain mapping, selective deletion mutagenesis, crystallization\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structural characterization by DXMS with mutagenesis, single lab\",\n      \"pmids\": [\"15964548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RIZ1 (PRDM2) associates with the promoter region of IGF-1 and increases histone H3 lysine 9 methylation at that promoter; forced RIZ1 expression in CML blast crisis cell lines decreases IGF-1 receptor activation and downstream ERK1/2 and AKT signaling.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), cDNA microarray, forced expression, Western blotting for signaling components, IGF-1 blocking antibody\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating promoter binding and H3K9 methylation combined with functional pathway analysis, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"16953217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The solution NMR structure of the RIZ1 PR domain reveals a typical SET fold including a C-terminal pseudo-knot; the domain does not have detectable affinity for the methyl donor by-product S-adenosyl-L-homocysteine (SAH) but interacts with a synthetic peptide comprising residues 1–20 of histone H3.\",\n      \"method\": \"NMR structure determination, SAH binding assay, histone H3 peptide binding\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — solution NMR structure with functional binding characterization, single lab but rigorous structural study\",\n      \"pmids\": [\"18082620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RIZ1 is required for the cancer-preventive benefit of a methyl-balanced diet in mice; methyl-balanced diet upregulates RIZ1 expression, and higher RIZ1 activity correlates with increased H3K9 methylation at RIZ1 target gene promoters as shown by ChIP.\",\n      \"method\": \"Mouse dietary experiment (RIZ1 knockout vs. wild type), microarray gene expression, ChIP, quantitative RT-PCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic epistasis with ChIP functional readout, single lab\",\n      \"pmids\": [\"18852888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RIZ1 epigenetic silencing in hepatocellular carcinoma involves both DNA promoter methylation and H3K9 trimethylation; 5-Aza-dC promotes conversion of H3K9me3 to H3K9ac at the RIZ1 promoter preceding re-expression; HDAC1 (but not HDAC3) is downregulated by 5-Aza-dC/TSA treatment.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), methylation-specific PCR, RT-PCR, immunohistochemistry, demethylating/HDAC inhibitor treatment\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating histone modification dynamics at promoter, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"20675009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RIZ1 expression is induced by RANKL in macrophage-like cells and is required for osteoclast formation; RIZ1 siRNA knockdown reduces NFATc1 expression and impairs TRAP-positive multinucleated osteoclast formation.\",\n      \"method\": \"siRNA knockdown, RANKL stimulation assay, TRAP staining, Western blotting for NFATc1\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA loss-of-function with defined molecular and cellular phenotype, single lab\",\n      \"pmids\": [\"20417662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"RIZ1 expression induced by TNF-α in monocytic leukemia cells is dependent on NF-κB and AKT signaling; RIZ1 in turn augments p53 expression, and RIZ1 silencing prevents p53 induction, resulting in enhanced proliferation.\",\n      \"method\": \"Pathway inhibition, siRNA knockdown, Western blotting, proliferation assay\",\n      \"journal\": \"Cancer investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA loss-of-function with defined signaling pathway readout, single lab\",\n      \"pmids\": [\"20594067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"An estrogen-responsive element (ERE) within the RIZ promoter 2 (driving RIZ2 expression) is regulated in a ligand-specific manner by ERα through both its AF1 and AF2 domains; association of topoisomerase IIβ with this promoter confirms transcriptional activation by estrogen, with cyclical H3K9 methylation patterns comparable to other estrogen-regulated promoters.\",\n      \"method\": \"Promoter reporter assay, ChIP for ERα and histone modifications, topoisomerase IIβ ChIP, transfection with ERα domain mutants\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple ChIP assays plus functional reporter with domain mutants, single lab\",\n      \"pmids\": [\"21503890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PR-Set7/KMT5a directly and specifically binds the C-terminus of Riz1/PRDM2; the PR/SET domain of Riz1 preferentially monomethylates H3K9; the PR-Set7-binding domain of Riz1 is required for its nuclear localization and for maintenance of the H4K20me1-H3K9me1 trans-tail histone code. Cancer-associated frameshift mutations truncating Riz1 and preventing PR-Set7 binding abolish tumor suppression; both the methyltransferase domain and PR-Set7-binding domain are required for tumor suppressor function.\",\n      \"method\": \"Direct binding assay (Co-IP, pulldown), H3K9 methyltransferase in vitro assay, nuclear localization by imaging, tumor suppression assay (proliferation/apoptosis), histone modification analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro enzymatic assay, direct binding, localization linked to function, domain mutagenesis with phenotypic readout, single rigorous study\",\n      \"pmids\": [\"24423864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PRDM2/RIZ is enriched in quiescent muscle stem cells and controls reversible quiescence in cultured myoblasts; PRDM2 associates with >4400 promoters in G0 myoblasts (55% marked with H3K9me2), and knockdown alters histone methylation at Myogenin and CyclinA2 (CCNA2) promoters. PRDM2 protein interacts with PRC2 component EZH2 and regulates EZH2's association with a G0-specific bivalent chromatin domain at the CCNA2 locus, acting upstream of the PRC2 complex.\",\n      \"method\": \"ChIP-seq, ChIP-qPCR, siRNA knockdown, Co-IP (PRDM2-EZH2 interaction), flow cytometry, live imaging\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-seq, reciprocal Co-IP, functional knockdown with defined chromatin and cellular phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"26040698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The structural basis for RIZ1-Rb interaction was established: the acidic region (AR) of RIZ1 is intrinsically disordered and binds the pocket domain of Rb with submicromolar affinity; binding is mediated primarily by the short IRCDE motif within AR, analogous to the LXCXE motif of viral oncoproteins.\",\n      \"method\": \"NMR spectroscopy, isothermal titration calorimetry (ITC), fluorescence anisotropy, recombinant proteins\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple biophysical methods with recombinant proteins characterizing affinity and binding interface, single rigorous study\",\n      \"pmids\": [\"25640033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"History of alcohol dependence persistently decreases Prdm2 expression in the rat dorsomedial prefrontal cortex, with decreased H3K9me1; viral-vector knockdown of Prdm2 in dmPFC phenocopies dependence-induced increases in alcohol self-administration and compulsive drinking. ChIP-seq shows genes involved in synaptic communication are regulated by H3K9me1 in dependent rats.\",\n      \"method\": \"Viral vector knockdown in vivo, ChIP-seq for H3K9me1, behavioral assays, qRT-PCR\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo viral-vector loss-of-function with defined behavioral and epigenomic phenotype, ChIP-seq, multiple methods\",\n      \"pmids\": [\"27573876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Somatic PRDM2 c.4467delA frameshift mutation in colorectal cancer cells reduces global H3K9 dimethylation; correction to wild-type by genome editing restores H3K9me2, reduces migration, anchorage-independent growth and tumor growth in vivo; gene set enrichment analysis identifies regulation of EMT (with VIM as most regulated gene) as a central aspect of PRDM2 tumor suppressive action.\",\n      \"method\": \"CRISPR/genome editing (isogenic cell line correction), global histone methylation analysis, migration assay, anchorage-independent growth, xenograft tumor model, gene set enrichment analysis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isogenic genome-edited cell system with multiple orthogonal functional readouts and in vivo validation, single rigorous study\",\n      \"pmids\": [\"29228717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HBx (hepatitis B virus X protein) represses RIZ1 expression by upregulating DNMT1, which binds the RIZ1 promoter (shown by ChIP); this interaction is enhanced by HBx. Decreased miR-152 is involved in DNMT1 upregulation in HBx-transfected cells.\",\n      \"method\": \"ChIP, siRNA knockdown of DNMT1, HBx transfection, bisulfite sequencing, methylation-specific PCR\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating DNMT1 promoter binding plus siRNA rescue, single lab\",\n      \"pmids\": [\"28339081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RIZ1 directly binds the Akt3 gene promoter and represses its transcription with concomitant increase in H3K9 methylation at the promoter; overexpression of RIZ1 reduces Akt3 protein and luciferase reporter activity from the Akt3 promoter.\",\n      \"method\": \"In vitro promoter binding with recombinant protein, ChIP, luciferase reporter assay, Western blotting\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo promoter binding with functional reporter and histone modification readout, single lab\",\n      \"pmids\": [\"29367689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"YY1 protein binds the RIZ1 promoter and positively regulates its transcription in osteosarcoma cells; YY1 presence reduces H3K9 dimethylation at the promoter as shown by ChIP. Silencing of YY1 decreases RIZ1 protein expression.\",\n      \"method\": \"ChIP, promoter reporter assay, YY1 siRNA knockdown, RT-PCR, Western blot\",\n      \"journal\": \"Oncology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus promoter assay and siRNA loss-of-function, single lab\",\n      \"pmids\": [\"18488713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PRDM2 overexpression upregulates dopamine receptor D2 (D2DR) expression and inhibits ERK1/2 phosphorylation in MMQ prolactinoma cells; PRDM2 shows a synergistic effect with bromocriptine in inhibiting prolactin secretion and cell viability.\",\n      \"method\": \"Overexpression in cell line, Western blot for ERK phosphorylation, RT-PCR for D2DR, cell viability assay\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single lab, gain-of-function with defined signaling readout, moderate experimental rigor\",\n      \"pmids\": [\"25884948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"RIZ1 protein is localized to the nucleus in normal prostate epithelial cells; in cancer cells with higher Gleason score, RIZ1 shifts from nuclear to cytoplasmic localization. RIZ1 co-immunoprecipitates with both ERα and ERβ in estrogen-treated prostate epithelial cells.\",\n      \"method\": \"Immunohistochemistry, subcellular fractionation/localization, Co-IP with ERα and ERβ, RT-PCR\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Co-IP combined with localization in primary cells and tissue, single lab\",\n      \"pmids\": [\"19746436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRDM2 negatively regulates c-Myc expression in somatotroph adenoma GH3 cells; overexpression of PRDM2 induces G2/M arrest, apoptosis, and inhibits invasion, and elevates CDKN1A and CDKN1B levels. Combined with c-Myc inhibitor, PRDM2 further suppresses proliferation, establishing a functional PRDM2–c-Myc axis.\",\n      \"method\": \"Overexpression in GH3 cells, flow cytometry, transwell invasion assay, RT-PCR, Western blot, c-Myc inhibitor co-treatment\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — gain-of-function with molecular pathway readout and pharmacological epistasis, single lab\",\n      \"pmids\": [\"32044406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"RIZ1 negatively regulates UbcH10 (UBE2C) expression in a c-Myc-dependent manner in meningioma cells: RIZ1 overexpression decreases c-Myc which in turn reduces UbcH10, a c-Myc target gene, providing a RIZ1→c-Myc→UbcH10 regulatory axis.\",\n      \"method\": \"Overexpression, siRNA knockdown, Western blot, RT-PCR, reporter assay\",\n      \"journal\": \"American journal of translational research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, indirect epistasis inferred from expression changes, limited mechanistic validation\",\n      \"pmids\": [\"28560012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The isolated N-terminal PR domain of RIZ1 possesses intrinsic histone methyltransferase activity and tumor-suppressive (growth-inhibitory) activity in meningioma cells; microarray analysis of PR-domain-treated cells identifies c-Myc and TXNIP as putative H3K9 methylation downstream targets.\",\n      \"method\": \"Recombinant TAT-RIZ1-PR protein transduction, histone methyltransferase activity assay, microarray, xenograft tumor model\",\n      \"journal\": \"Biomaterials\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro enzymatic assay for methyltransferase activity of PR domain, in vivo tumor model, single lab\",\n      \"pmids\": [\"25934289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"RIZ1 knockdown in cholangiocarcinoma CCA cells (which show predominant nuclear localization of RIZ1) augments cell proliferation and migration, defining RIZ1 as a regulator of these processes in this cell type.\",\n      \"method\": \"siRNA knockdown, nuclear localization by microscopy, proliferation assay, migration assay\",\n      \"journal\": \"Asian Pacific journal of cancer prevention\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, siRNA with phenotypic readout but limited mechanistic detail\",\n      \"pmids\": [\"23098508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRDM2 phosphosites Ser643 and Ser421 are the predominant phosphorylation sites across large-scale phosphoproteomics datasets; ATR kinase is computationally predicted to phosphorylate these sites; co-regulated phosphosites are enriched in DNA damage response pathways. However, this is a computational/bioinformatic study and functional consequences of phosphorylation were not experimentally validated.\",\n      \"method\": \"Computational phosphoproteomics meta-analysis, expression co-regulation analysis, kinase prediction\",\n      \"journal\": \"3 Biotech\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — purely computational/bioinformatic; no direct experimental validation of phosphosite function\",\n      \"pmids\": [\"42179918\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRDM2/RIZ1 is a nuclear histone H3 lysine 9 mono/dimethyltransferase whose N-terminal PR/SET domain catalyzes H3K9 methylation, represses transcription at GC-rich promoters, interacts with the retinoblastoma protein (Rb) via an IRCDE/LXCXE-like motif, forms a ligand-dependent complex with estrogen receptor α (acting as an ERα co-activator), and is recruited to target gene promoters (including IGF-1, Akt3, CyclinA2) where it deposits repressive H3K9me1/2 marks; its tumor suppressive activity requires both the PR/SET methyltransferase domain and a C-terminal domain that binds PR-Set7/KMT5a (which is also required for nuclear localization and the H4K20me1-H3K9me1 trans-tail histone code), while the oncogenic RIZ2 isoform, produced from an internal promoter and lacking the PR domain, promotes proliferation and can antagonize RIZ1 function in a yin-yang fashion.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PRDM2 (RIZ) is a nuclear, sequence-specific zinc-finger protein that functions as a histone H3 lysine 9 methyltransferase and transcriptional repressor, and acts as a tumor suppressor whose loss promotes proliferation and malignant transformation [#7, #22]. The gene encodes two products through an internal promoter: RIZ1, which contains the catalytic N-terminal PR/SET domain, and RIZ2, which lacks it; RIZ1 is selectively lost in cancers while RIZ2 is retained, and the PR domain modulates repressor potency [#1, #2, #4]. The PR domain adopts a SET-like fold and possesses intrinsic methyltransferase activity, preferentially depositing repressive H3K9me1/2 marks; cancer-associated missense mutations cluster in this domain and reduce catalytic activity [#10, #12, #18, #30]. RIZ1 binds GC-rich/Sp1 elements through its first three zinc fingers and is recruited to target promoters including IGF-1 and Akt3, where it increases H3K9 methylation and dampens downstream ERK and AKT signaling [#2, #11, #24]. Full tumor suppressor function requires both the PR/SET methyltransferase domain and a C-terminal domain that directly binds PR-Set7/KMT5a, which is also necessary for nuclear localization and for maintaining the H4K20me1–H3K9me1 trans-tail histone code; truncating frameshift mutations that prevent this interaction abolish tumor suppression [#18]. PRDM2 also engages the chromatin machinery more broadly, interacting with the PRC2 component EZH2 to control bivalent chromatin and reversible quiescence at cell-cycle gene loci such as CCNA2 [#19]. Beyond chromatin, RIZ1 binds the retinoblastoma protein via an intrinsically disordered acidic region carrying an IRCDE/LXCXE-like motif and can form a ternary complex with Rb and E2F1 [#0, #3, #20], and it forms a ligand-dependent complex with estrogen receptor α acting as a co-activator [#5, #7]. PRDM2 is itself epigenetically silenced in tumors through DNA promoter methylation and H3K9 trimethylation, and its in vivo loss drives lymphoma and a broad tumor spectrum [#7, #14, #22]. Functionally, PRDM2 controls cellular quiescence, differentiation, and epithelial–mesenchymal transition, and in the nervous system H3K9me1-dependent PRDM2 activity in the prefrontal cortex regulates alcohol-dependence behaviors [#19, #21, #22].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Identifying PRDM2/RIZ as a direct Rb-binding nuclear protein placed it within the retinoblastoma tumor suppressor network and motivated study of its growth-control role.\",\n      \"evidence\": \"cDNA library screening for Rb-binding proteins and binding assays\",\n      \"pmids\": [\"7538672\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of the Rb interaction not established\", \"Binding interface not yet mapped\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing that an internal promoter generates PR-domain-containing RIZ1 and PR-domain-lacking RIZ2 defined the yin-yang isoform structure central to PRDM2 biology.\",\n      \"evidence\": \"Immunoprecipitation, immunoblot, RNase protection, immunofluorescence after transfection\",\n      \"pmids\": [\"9006946\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic role of the PR domain not yet demonstrated\", \"Functional divergence of isoforms not yet established\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Mapping DNA-binding to the first three zinc fingers and a central repressor domain, with stronger repression by RIZ1, showed the protein is a sequence-specific transcriptional repressor whose PR domain modulates activity.\",\n      \"evidence\": \"Recombinant DNA-binding assays, GAL4 reporter domain mapping, transfection; plus in vitro Rb-pocket ternary complex with E2F1\",\n      \"pmids\": [\"9334209\", \"9223517\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo target genes not identified\", \"Link between DNA binding and histone modification not yet made\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrating that RIZ1 (but not RIZ2) induces G2/M arrest and apoptosis and is selectively lost in breast cancer established isoform-specific tumor suppression.\",\n      \"evidence\": \"Adenoviral forced expression, flow cytometry, viability assays in breast cancer cells\",\n      \"pmids\": [\"9766644\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of growth arrest not defined\", \"Mechanism of selective RIZ1 loss not addressed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showing a ligand-dependent RIZ–ERα complex and estrogen-responsive promoter targeting expanded PRDM2's role into nuclear hormone receptor signaling.\",\n      \"evidence\": \"Co-IP, domain mapping, CAST/EMSA, reporter assays in MCF-7 and rat endometrium\",\n      \"pmids\": [\"10706618\", \"10544042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether co-activation involves methyltransferase activity unresolved\", \"Direct vs indirect ERα contact not fully defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Knockout of the RIZ1 locus causing lymphoma and tumors, with PR-domain mutations clustering in human cancers, provided genetic proof of tumor suppression centered on the methyltransferase domain.\",\n      \"evidence\": \"Targeted mouse knockout, human tumor mutation sequencing, ERα transactivation assays; plus differentiation induction in HL60 cells\",\n      \"pmids\": [\"11544182\", \"11591891\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymatic activity of the PR domain not yet directly measured\", \"Direct substrate of the PR domain not yet defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Solving the PR-domain structure as a SET-like fold that binds the H3 N-terminal peptide established the molecular basis for PRDM2 acting as an H3K9 methyltransferase.\",\n      \"evidence\": \"Solution NMR structure, SAH and H3 peptide binding assays; earlier DXMS structural mapping\",\n      \"pmids\": [\"18082620\", \"15964548\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic mechanism and methyl-donor handling unclear (no SAH affinity detected)\", \"Specific H3K9 lysine targeting not confirmed structurally\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"ChIP demonstrating RIZ1 occupancy and H3K9 methylation at the IGF-1 promoter with reduced downstream ERK/AKT signaling connected chromatin repression to a defined oncogenic signaling output.\",\n      \"evidence\": \"ChIP, microarray, forced expression, signaling Western blots in CML blast crisis cells\",\n      \"pmids\": [\"16953217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide target spectrum not yet defined\", \"Direct vs indirect signaling effects not separated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying direct KMT5a/PR-Set7 binding to the RIZ1 C-terminus as required for nuclear localization, the H4K20me1–H3K9me1 trans-tail code, and tumor suppression unified catalysis, localization, and cancer-associated truncations into one mechanistic model.\",\n      \"evidence\": \"Co-IP/pulldown, in vitro H3K9 methyltransferase assay, imaging, domain mutagenesis with phenotypic readout\",\n      \"pmids\": [\"24423864\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structure of the RIZ1–PR-Set7 complex unknown\", \"How the trans-tail code is read by downstream factors unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defining the disordered acidic region with an IRCDE motif as the submicromolar Rb-pocket binding element clarified the structural basis of the long-known RIZ1–Rb interaction.\",\n      \"evidence\": \"NMR, ITC, fluorescence anisotropy with recombinant proteins\",\n      \"pmids\": [\"25640033\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular consequence of competing with E2F for Rb not established\", \"Regulation of the interaction in vivo unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showing PRDM2 enrichment in quiescent muscle stem cells, genome-wide promoter occupancy with H3K9me2, and interaction with EZH2 positioned PRDM2 as an upstream regulator of bivalent chromatin and reversible quiescence.\",\n      \"evidence\": \"ChIP-seq, ChIP-qPCR, siRNA, Co-IP, flow cytometry, live imaging; plus isolated PR-domain transduction with intrinsic HMT activity\",\n      \"pmids\": [\"26040698\", \"25934289\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of PRDM2-directed EZH2 recruitment not defined\", \"Relationship between H3K9me2 and PRC2-deposited marks at shared loci unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"In vivo viral knockdown linking PRDM2/H3K9me1 loss in the prefrontal cortex to compulsive alcohol drinking extended PRDM2's epigenetic function to neurobehavioral regulation.\",\n      \"evidence\": \"Viral-vector knockdown, ChIP-seq for H3K9me1, behavioral assays in rats\",\n      \"pmids\": [\"27573876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific synaptic target genes mediating behavior not pinpointed\", \"Upstream signals lowering PRDM2 in dependence unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Isogenic correction of a somatic PRDM2 frameshift restoring global H3K9me2 and reversing EMT/tumor phenotypes provided causal evidence that catalytic loss drives malignancy through EMT regulation.\",\n      \"evidence\": \"CRISPR isogenic correction, global histone methylation analysis, migration/anchorage-independent growth, xenograft, GSEA in colorectal cancer; plus HBx/DNMT1-mediated promoter silencing\",\n      \"pmids\": [\"29228717\", \"28339081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct EMT target genes bound by PRDM2 not mapped\", \"Whether VIM is a direct or indirect target unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Accumulating gain/loss-of-function studies define recurrent PRDM2 regulatory axes (Akt3 repression, c-Myc/UBE2C and p53 modulation, D2DR upregulation) but their direct chromatin basis is incompletely resolved.\",\n      \"evidence\": \"Overexpression/knockdown with reporter, ChIP, and signaling readouts across prolactinoma, somatotroph, meningioma, and leukemia cells\",\n      \"pmids\": [\"29367689\", \"32044406\", \"28560012\", \"25884948\", \"20594067\", \"20417662\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect regulation of c-Myc/p53 not separated by chromatin occupancy\", \"Several axes rest on single-lab overexpression studies\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PRDM2 activity is post-translationally controlled and how its catalytic and scaffolding functions are integrated to direct target selectivity remain open.\",\n      \"evidence\": \"No experimentally validated regulatory mechanism in the timeline; phosphosite/ATR predictions are computational only\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Phosphorylation sites Ser643/Ser421 and ATR regulation not experimentally validated\", \"No structure of full-length PRDM2 or its multiprotein complexes\", \"Rules governing genome-wide target promoter selection unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [10, 18, 22, 30]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 7, 9, 24]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [2, 6, 24]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [12, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 18, 27, 31]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [11, 19, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [11, 18, 19, 22]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 24]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [4, 19, 28]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RB1\", \"ESR1\", \"KMT5a\", \"EZH2\", \"ESR2\", \"E2F1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}